德谷胰岛素与利拉鲁肽复方制剂IDegLira在2型糖尿病综合管理中的优势  

The Advantages of the Antihyperglycemic Drug IDegLira in the Comprehensive Management of Type 2 Diabetes

作　　者：高天舒[1] GAO Tianshu(First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang Liaoning 110033,China)

机构地区：[1]辽宁中医药大学附属医院,辽宁沈阳110033

出　　处：《药品评价》2021年第16期961-964,共4页Drug Evaluation

摘　　要：糖尿病的治疗目的是通过规范治疗,防治各种糖尿病并发症,延缓病情发展,降低死亡率和改善生活质量。糖尿病的远期预后与多种危险因素有关,改善糖尿病患者的预后,必须着眼于多重危险因素的干预。多国指南也推荐,应对2型糖尿病患者进行多重风险因素管理。德谷胰岛素与利拉鲁肽的复方制剂IDegLira有效结合了胰岛素的强效降糖和利拉鲁肽的安全降糖、减轻体质量和减少主要不良心血管事件的长处,有望成为糖尿病综合管理的新选择。The purpose of the diabetic treatment is to prevent a variety of complications,delay the development of disease,reduce mortality and improve the quality of life through standardized therapy.The long-term prognosis of diabetes is related to multiple risk factors.To improve the prognosis of diabetic patients,must focus on the interventionsfor multiple risk factors.Multinational guidelines also recommend that patients with type 2 diabetes mellitusshould be managed with interventions for multiple risk factors.IDegLira,a compound preparation of insulin degludec and liraglutide,effectively combines the potent antihyperglycemic effects of insulin and the advantages of safely antihyperglycemic effects,weight loss and less cardiovascular events of liraglutide.It is expected to become a new option for comprehensive management of T2DM.

关 键 词：糖尿病 2型 综合管理 基础胰岛素 GLP-1受体激动剂 IDegLira 

分 类 号：R587.1[医药卫生—内分泌]